1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-353.
3. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-612.
4. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.
5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but No Other Histologic Features, is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015;149:389-397.
6. Byrne CD, Targher, G. NAFLD: A multisystem disease. J Hepatol 2015;62:47-64.
7. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Hepatology 2017;65:1557-1565.
8. Castéra L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-675.
9. Herzer K, Roeb E. Modernes Management und neue Herausforderungen bei Fettlebererkrankungen. Der Klinikarzt 2016;45:596-601.
10.Dancygier, H. Pathogenese und Therapie der nichtalkoholischen Fettlebererkrankungen:
Von der Fettleber zur Zirrhose. Dtsch Arztebl 2006; 103(19): A 1301-1307.
11.Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
12.Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-1894.
13.Arab JP, Arrese M, Trauner M. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annu Rev Pathol 2018;13:321-350.
28 14.Diehl AM, Day, C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N
Engl J Med 2017;377:2063-2072.
15.Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
16.Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-2119.
17.Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatoheaptitis. Gut 2005;54:303-306.
18. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2004;286:E8-13.
19.Wree A, Geisler LJ, Tacke F. Microbiome & NASH - partners in crime driving progression of fatty liver disease. Z Gastroenterol 2019;57:871-882.
20.Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H. Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute ad chronic liver diseases. Z Gastroenterol 2014;52:290-295.
21.Malhi H, Gores GJ. Molecular mechnisms of lipotoxicity in nonalcoholic fatty liver disease.
Semin Liver Dis 2008;28:360-369.
22.Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001;80:230-239.
23.Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, et al.
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-572.
24.Bantel H, Lügering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al.
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078-1087.
25. Ku NO, Strnad P, Bantel H, Omary MB. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 2016;64:966-976.
26.Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
Gastroenterology 2003;125:437-443.
29 27.Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ.
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-1078.
28.Bantel H, John K, Schulze-Osthoff K. Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments. Am J Gastroenterol 2014;109:140-141.
29.Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455-464.
30. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Hepatology 2013;57:1394-1406.
31.Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Hepatology 2007;45:846-854.
32.Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014;39:254-269.
33.Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008;6:1249-1254.
34.Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-649.
35.Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011;54:1224-1229.
36.Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, et al. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin
Gastroenterol 2010;44:440-447.
30 37.Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology 2005;41:1313-1321.
38.EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-1402.
39.Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015;53:668-723.
40.Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR.
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.
Am J Gastroenterol 1999;94:2467-2474.
41.Brunt EM, Tiniakos DG. Alcoholic and non-alcoholic fatty liver disease. In: Odze RD, Goldblum JR, Crawford JM. Surgical Pathology of the GI tract, liver, biliary tract and pancreas. Philadelphia: Saunders, 2009:1087-1460.
42.Strnad P, Zatloukal K, Stumptner C, Kulaksiz H, Denk H. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta 2008;1782:764-774.
43.Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al.
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis. Hepatology 2018;68:349-360.
44.Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Lancet 2015;385:956-965.
45.Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol 2010;22:643-650.
46.Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009;51:371-379.
47. Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, Berg CL.
NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 2009;8:346-352.
48.Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-1044.
49.Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
31 50.Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-835.
51.Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al.
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199-208.
52.Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, Li MK, et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300-305.
53. Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-1871.
54.Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, et al.
Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134-144.
55.Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
Hepatology 2010;51:454-462.
56.Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015;35:1566-1573.
57.Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.
58.Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-1251.
59.Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al.
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;14;6:6.
32 60.Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al.
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol.
2006;10;6:34.
61.Sterling RK, Lissen E, Clumeck N, et. al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43:1317-1325.
62.Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-1112.
63.Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, et al. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther 2012;36:1057-1066.
64.Seidel N, Volkmann X, Länger F, Flemming P, Manns MP, Schulze-Osthoff K, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005;42:113-120.
65. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al. Review article: the diagnosis of alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37:392-400.
66.McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148-1155.
67.Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al.
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-2130.
68.Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
J Hepatol 2013;59:550-556.
69.Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010;30:226-231.
70.Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis 2010;30:402-410.
71.Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663.
33 72.Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor
IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308:1191-1196.
73.Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat 2012;19:278-282.
74.Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013;108:1526-1531.
75. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al.
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care 2015;38:1347-1355.
34
I Lebenslauf
Neele Stöckmann
Geburtsdatum: 10.11.1987 Geburtsort: Göttingen Ausbildung
Juni 2006 Abitur am Georg-Forster-Gymnasium in Berlin-Lichtenberg
08/2006 - 07/2007 Freiwilliges Soziales Jahr in der Camphill Community Mourne Grange (Nordirland, Arbeit mit geistig behinderten Erwachsenen)
10/2007 - 12/2013 Studium der Humanmedizin an der Ruhr-Universität Bochum 09/2009 Erster Abschnitt der Ärztlichen Prüfung
09/2009 - 05/2010 Studium an der Université François Rabelais de Tours (Frankreich), Teilnahme am Erasmusprogramm
08/2012 - 06/2013 Praktisches Jahr:
08/2012 - 10/2012 Chirurgie im St. Josef-Hospital Bochum
10/2012 - 12/2012 Chirurgie im Royal Hallamshire/Northern General Hospital in Sheffield (England)
12/2012 - 03/2013 Innere Medizin im Spital Emmental in Burgdorf (Schweiz) 04/2013 - 06/2013 Anästhesie im Marienhospital Herne
12/2013 2. Abschnitt der Ärztlichen Prüfung
Berufstätigkeit
seit 02/2014 Assistenzärztin in der Klinik für Gastroenterologie, Hepatologie und Endokrinologie der Medizinischen Hochschule Hannover
Hannover, Dezember 2019
35
II Erklärung nach §2 Abs. 2 Nrn. 6 und 7 der Promotionsordnung
Ich erkläre, dass ich die der Medizinischen Hochschule Hannover zur Promotion eingereichte Dissertation mit dem Titel
Neuer diagnostischer Algorithmus zur Beurteilung der Krankheitsaktivität bei NAFLD
in der Klinik für Gastroenterologie, Hepatologie und Endokrinologie unter Betreuung von Frau Professor Heike Bantel mit der Unterstützung von Mitarbeiterinnen der Arbeitsgruppe Frau Stephanie Liebig und Frau Franziska Wandrer ohne sonstige Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die dort aufgeführten Hilfsmittel benutzt habe.
Die Gelegenheit zum vorliegenden Promotionsverfahren ist mir nicht kommerziell vermittelt worden. Insbesondere habe ich keine Organisation eingeschaltet, die gegen Entgelt Betreuerinnen und Betreuer für die Anfertigung von Dissertationen sucht oder die mir obliegenden Pflichten hinsichtlich der Prüfungsleistungen für mich ganz oder teilweise erledigt.
Ich habe diese Dissertation bisher an keiner in- oder ausländischen Hochschule zur Promotion eingereicht. Weiterhin versichere ich, dass ich den beantragten Titel bisher noch nicht erworben habe.
36
III Danksagung
Mein Dank gilt insbesondere meiner Doktormutter Frau Professor Heike Bantel für die Bereitstellung des Themas und die gute Betreuung, die sich durch interessante Diskussionen, Geduld und eine sehr verlässliche Kommunikation während der Erstellung der Arbeit auszeichnete. Den Mitarbeiterinnen aus der Arbeitsgruppe von Frau Professor Bantel, Stephanie Liebig und Franziska Wandrer, danke ich für ihre Hilfsbereitschaft und Unterstützung bei Fragen zur Datendokumentation und statistischen Auswertung.
Ein besonderer Dank gilt meinen Eltern Fritz und Vera Stöckmann für ihre selbstlose Unterstützung und ein immer offenes Ohr auf meinem bisherigen Lebensweg.
Weiter danke ich meinen Freunden Stefan Surhoff, Susanne Krusche und Golnar Rath, allesamt Mediziner, die mich an den Erfahrungen bei der Erstellung ihrer Promotion teilhaben lassen und mich moralisch unterstützt haben. Abschließend danke ich meiner ersten Arbeitskollegin auf Station, Martha Kirstein, die mich mit Geduld in die stationäre Patientenversorgung eingeführt hat und durch die der Kontakt für die Promotion erst zustande gekommen ist.
37
IV Veröffentlichung
Diese Promotionsarbeit bildete die Grundlage einer multizentrischen Validierungsstudie, die im August 2019 online veröffentlicht wurde:
Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, et al. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clin Transl Gastroenterol.
2019;10:e00066